The β-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter

被引:377
作者
Livermore, David M. [1 ]
Woodford, Neil [1 ]
机构
[1] Hlth Protect Agcy Ctr Infect, Antiobiot Resistance Monitoring & Reference Lab, London NW9 5EQ, England
关键词
D O I
10.1016/j.tim.2006.07.008
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Over the past 60 years, the use of successive generations of beta-lactam antibiotics has selected successive generations of beta-lactamase enzymes, each more potent than the last. Currently, rising problems include CTX-M extended-spectrum beta-lactamases (ESBLs), plasmid-mediated AmpC beta-lactamases and KPC carbapenemases in Enterobacteriaceae, while OXA- and metallo-carbapenemases are of growing importance in Acinetobacter spp. and (less so) in other non-fermenters. Escherichia coli isolates with CTX-M ESBLs are spreading multiresistance in the,community and in hospitals, while carbapenemase-producing Acinetobacter spp., mostly from intensive care, are among the most multiresistant nosocomial bacteria known and are often susceptible only to polymyxins and, potentially, tigecycline. This review discusses the epidemiology and microbiology of these resistance problems, along with possible solutions.
引用
收藏
页码:413 / 420
页数:8
相关论文
共 70 条
[41]   INVALIDITY FOR PSEUDOMONAS-AERUGINOSA OF AN ACCEPTED MODEL OF BACTERIAL PERMEABILITY TO BETA-LACTAM ANTIBIOTICS [J].
LIVERMORE, DM ;
DAVY, KWM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (05) :916-921
[42]   Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa:: Our worst nightmare? [J].
Livermore, DM .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (05) :634-640
[43]   The threat from the pink corner [J].
Livermore, DM .
ANNALS OF MEDICINE, 2003, 35 (04) :226-234
[44]   CTX-M: changing the face of ESBLs in the UK [J].
Livermore, DM ;
Hawkey, PM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 56 (03) :451-454
[45]   Potentiation of beta-lactams against Pseudomonas aeruginosa strains by Ro 48-1256, a bridged monobactam inhibitor of AmpC beta-lactamases [J].
Livermore, DM ;
Chen, HY .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (03) :335-343
[46]   Resistance to cefepime and cefpirome due to a 4-amino-acid deletion in the chromosome-encoded AmpC β-lactamase of a Serratia marcescens clinical isolate [J].
Mammeri, H ;
Poirel, L ;
Bemer, P ;
Drugeon, H ;
Nordmann, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (03) :716-720
[47]   Ambler class A extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. in Canadian hospitals [J].
Mulvey, MR ;
Bryce, E ;
Boyd, D ;
Ofner-Agostini, M ;
Christianson, S ;
Simor, AE ;
Paton, S .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (04) :1204-1214
[48]   Dissemination of CTX-M type β-lactamases in Enterobacteriaceae isolates in the people's Republic of China [J].
Munday, CJ ;
Xiong, J ;
Li, C ;
Shen, D ;
Hawkey, PM .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2004, 23 (02) :175-180
[49]   IN-VITRO EVALUATION OF THE 4 BETA-LACTAMASE INHIBITORS - BRL42715, CLAVULANIC ACID, SULBACTAM, AND TAZOBACTAM [J].
MURATANI, T ;
YOKOTA, E ;
NAKANE, T ;
INOUE, E ;
MITSUHASHI, S .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 32 (03) :421-429
[50]   Doripenem versus Pseudomonas aeruginosa in vitro:: Activity against characterized isolates, mutants, and transconjugants and resistance selection potential [J].
Mushtaq, S ;
Ge, YG ;
Livermore, DM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (08) :3086-3092